HAOHAI BIOTEC News

The highest single transaction price exceeds 0.5 million yuan! The small peak in medical beauty before the festival "arrives as scheduled", and the differentiation of Institutions intensifies further | Fax.

① With the Spring Festival approaching, the medical beauty Industry is experiencing a small surge in Consumer spending, and medium to large medical beauty Institutions have recently seen a significant increase in customer flow. ② Hyaluronic acid, facial rejuvenation injections, and collagen, which have short recovery times and clear effects, remain the "favorites" of Consumers before the holiday. ③ The differentiation among medical beauty Institutions of different sizes is intensifying.

cls.cnJan 18 07:03 ET

HAOHAI BIOTEC (06826.HK) spent 1.229 million yuan to buy back 0.0214 million A-shares on January 16.

Gelonghui reported on January 16 that HAOHAI BIOTEC (06826.HK) announced it spent 1.229 million yuan to repurchase 0.0214 million A-shares on January 16, 2025, with a repurchase price per share of 57.34-57.55 yuan.

Gelonghui FinanceJan 16 04:36 ET

HAOHAI BIOTEC (06826.HK) spent 0.9383 million yuan to repurchase 0.0164 million A-shares on January 15.

Gelonghui reported on January 15 that HAOHAI BIOTEC (06826.HK) announced that on January 15, 2025, it spent 0.9383 million yuan to repurchase 0.0164 million A-shares, with a repurchase price of 57.07-57.44 yuan per share.

Gelonghui FinanceJan 15 04:12 ET

HAOHAI BIOTEC (06826.HK) spent 0.53 million Hong Kong dollars to repurchase 0.022 million shares on January 13.

Gelonghui reported on January 13 that HAOHAI BIOTEC (06826.HK) announced that on January 13, it spent 0.53 million Hong Kong dollars to repurchase 0.022 million shares.

Gelonghui FinanceJan 13 05:28 ET

HAOHAI BIOTEC (06826) spent 0.4923 million HKD to buy back 0.02 million shares on January 10.

HAOHAI BIOTEC (06826) announced that on January 10, 2025, the company invested 0.4923 million...

Zhitong FinanceJan 10 04:18 ET

HAOHAI BIOTEC (06826) spent HKD 0.6519 million on January 9 to repurchase 0.026 million shares.

HAOHAI BIOTEC (06826) announced that it will spend 0.6519 million Hong Kong dollars to repurchase shares on January 9, 2025...

Zhitong FinanceJan 9 04:29 ET

HAOHAI BIOTEC (06826.HK) spent 0.254 million Hong Kong dollars to repurchase 0.01 million shares on January 8.

On January 8, Gelonghui reported that HAOHAI BIOTEC (06826.HK) announced it spent HKD 0.254 million to repurchase 0.01 million shares on January 8, 2025, with a repurchase price of HKD 25.4 per share.

Gelonghui FinanceJan 8 04:30 ET

HAOHAI BIOTEC (06826.HK) repurchased 0.039 million shares on January 2, spending 1.005 million Hong Kong dollars.

Gelonghui, January 2nd | HAOHAI BIOTEC (06826.HK) announced that on January 2, 2025, it spent 1.005 million Hong Kong dollars to repurchase 0.039 million shares at a price of 25.4-26 Hong Kong dollars per share.

Gelonghui FinanceJan 2 04:43 ET

Shanghai Haohai Biological Technology (688366.SH): Cumulatively repurchased 0.21% of shares.

On January 2, Gelonghui reported that Shanghai Haohai Biological Technology (688366.SH) announced that by December 2024, the company had cumulatively repurchased 354,596 A-shares through centralized price bidding, accounting for 0.15% of the company's total share capital of 233,193,695 shares, with a maximum Fill Price of 63.20 yuan/share, a minimum Fill Price of 60.58 yuan/share, and a total purchase amount of 21,850,342.17 yuan (excluding stamp duty, transaction commission, and other trading costs). As of December 31, 2024, the company had cumulatively repurchased A-shares through centralized price bidding.

Gelonghui FinanceJan 2 03:50 ET

Statistics on the abnormal share of Zhitong Hong Kong Stock Connect | January 1.

Statistics on abnormal changes in the proportion of the Stock Connect as of December 31, 2024.

Zhitong FinanceDec 31 19:35 ET

On December 31, HAOHAI BIOTEC (06826) spent 0.71929 million Hong Kong dollars to repurchase 0.027 million shares listed in Hong Kong.

HAOHAI BIOTEC (06826) announced that on December 31, 2024, it spent 0.71929 million Hong Kong dollars to repurchase 2...

Zhitong FinanceDec 31, 2024 03:46 ET

HAOHAI BIOTEC (06826.HK) has completed the cancellation of 0.9966 million H-shares.

Gelonghui, December 30th丨HAOHAI BIOTEC (06826.HK) announced that as of December 30, 2024, the company has completed the cancellation of 996,600 H shares repurchased. After the cancellation, the total share capital of the company changed from 234,190,295 shares to 233,193,695 shares.

Gelonghui FinanceDec 30, 2024 04:59 ET

HAOHAI BIOTEC (06826.HK) spent 0.2944 million yuan to repurchase 0.011 million shares on December 30.

Gelonghui, December 30丨HAOHAI BIOTEC (06826.HK) announced that on December 30, 2024, it spent 0.2944 million Hong Kong dollars to repurchase 0.011 million A-shares, with a repurchase price of 26.6-26.8 Hong Kong dollars per share. On the same day, the company spent 2.6256 million yuan to repurchase 0.043 million shares on the Shanghai Stock Exchange.

Gelonghui FinanceDec 30, 2024 04:10 ET

HAOHAI BIOTEC (06826.HK) spent 1.948 million yuan to repurchase 0.0315 million A shares on December 27.

Gelonghui, December 27th丨HAOHAI BIOTEC (06826.HK) announced that on December 27, 2024, it spent 1.948 million yuan to repurchase 0.0315 million A-shares at a repurchase price of 61.62-62 yuan per share.

Gelonghui FinanceDec 27, 2024 05:45 ET

Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.

① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.

cls.cnDec 24, 2024 04:16 ET

HAOHAI BIOTEC (06826.HK) spent 0.2913 million HKD to repurchase 0.011 million shares on December 23.

Gelonghui reported on December 23 that HAOHAI BIOTEC (06826.HK) announced that on December 23, 2024, it spent 0.2913 million Hong Kong dollars to repurchase 0.011 million shares, with a repurchase price of 26.45-26.5 Hong Kong dollars per share.

Gelonghui FinanceDec 23, 2024 04:06 ET

Recent 6.3% Pullback Would Hurt Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Insiders

Simply Wall StDec 20, 2024 18:32 ET

HAOHAI BIOTEC (06826.HK) spent 1.0705 million HKD to repurchase 0.04 million shares on December 20.

Gelonghui reported on December 20 that HAOHAI BIOTEC (06826.HK) announced it spent HKD 1.0705 million to repurchase 0.04 million shares, with a repurchase price of HKD 26.7-26.85 per share. On the same day, the company spent RMB 1.9862 million to repurchase 0.032 million shares, with a repurchase price of RMB 61.94-62.2 per share.

Gelonghui FinanceDec 20, 2024 04:17 ET

HAOHAI BIOTEC (06826.HK) spent 1.048 million Hong Kong dollars to repurchase 0.039 million shares on December 19.

Gelonghui reported on December 19 that HAOHAI BIOTEC (06826.HK) announced that on December 19, it spent 1.048 million Hong Kong dollars to repurchase 0.039 million shares, with a repurchase price of 26.75-27 Hong Kong dollars per share.

Gelonghui FinanceDec 19, 2024 04:29 ET

HAOHAI BIOTEC (06826.HK) spent 0.282 million Hong Kong dollars to repurchase 0.0104 million shares on December 18.

On December 18, Gelonghui reported that HAOHAI BIOTEC (06826.HK) announced that on December 18, it spent 0.282 million Hong Kong dollars to repurchase 0.0104 million shares.

Gelonghui FinanceDec 18, 2024 04:54 ET